Abstract
Wastewater surveillance has emerged as a useful tool in the public health response to the COVID-19 pandemic. While wastewater surveillance has been applied at various scales to monitor population-level COVID-19 dynamics, there is a need for quantitative metrics to interpret wastewater data in the context of public health trends. We collected 24-hour composite wastewater samples from March 2020 through May 2021 from a Massachusetts wastewater treatment plant and measured SARS-CoV-2 RNA concentrations using RT-qPCR. We show that the relationship between wastewater viral titers and COVID-19 clinical cases and deaths varies over time. We demonstrate the utility of three new metrics to monitor changes in COVID-19 epidemiology: (1) the ratio between wastewater viral titers and clinical cases (WC ratio), (2) the time lag between wastewater and clinical reporting, and (3) a transfer function between the wastewater and clinical case curves. We find that the WC ratio increases after key events, providing insight into the balance between disease spread and public health response. We also find that wastewater data preceded clinically reported cases in the first wave of the pandemic but did not serve as a leading indicator in the second wave, likely due to increased testing capacity. These three metrics could complement a framework for integrating wastewater surveillance into the public health response to the COVID-19 pandemic and future pandemics.
Competing Interest Statement
MM and NG are cofounders of Biobot Analytics. EJA is advisor to Biobot Analytics. CD, NE, MI, and KAM are employees at Biobot Analytics, and all these authors hold shares in the company.
Funding Statement
This work was supported by the Center for Microbiome Informatics and Therapeutics and Intra-CREATE Thematic Grant (Cities) grant NRF2019-THE001-0003a to JT and EJA; National Institute on Drug Abuse of the National Institutes of Health award numbers K23DA044874 to PRC; and R44DA051106 to MM and PRC, Hans and Mavis Psychosocial Foundation funding, and e-ink corporation funding to PRC; funds from the Massachusetts Consortium on Pathogen Readiness and China Evergrande Group to TBE, PRC, MM, and EJA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding institutions.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis uses publicly available data, without human subjects research, so no IRB approval was sought.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data on the concentration of SARS-CoV-2 viral RNA in Massachusetts wastewater is publicly available at https://www.mwra.com/biobot/biobotdata.htm.
